21st Apr 2022 14:37
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Completes acquisition of Custopharm Inc from Water Street Healthcare Partners, following approval from the US Federal Trade Commission. Back in September, Hikma agreed to buy the California-based generic injectable products company for a total of up to USD425 million. Deal will add up to 13 approved products and additional pipeline products.
Current stock price: 2,046.00 pence
12-month change: down 16%
By Paul McGowan; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Hikma Pharmaceuticals